KYMR — Kymera Therapeutics Income Statement
0.000.00%
- $1.83bn
- $1.31bn
- $78.59m
- 68
- 17
- 74
- 52
Annual income statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.93 | 34 | 72.8 | 46.8 | 78.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 45.1 | 80.3 | 173 | 208 | 244 |
Operating Profit | -42.2 | -46.3 | -101 | -161 | -166 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -41.2 | -45.6 | -100 | -155 | -147 |
Net Income After Taxes | -41.2 | -45.6 | -100 | -155 | -147 |
Net Income Before Extraordinary Items | |||||
Net Income | -41.2 | -45.6 | -100 | -155 | -147 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -41.2 | -54.6 | -100 | -155 | -147 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.956 | -1.23 | -2.09 | -2.87 | -2.52 |
Dividends per Share |